Skip to main content

Advertisement

Table 2 Selected therapy characteristics of the total study cohort with univariable analyses of BB-CAM use

From: Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy

CHARACTERISTICS ALL PATIENTS BB-CAM p 1
   User Non-user
Total Count % of all patients Count % of Total Count % of Total
448 100% 332 74.1% 116 25.9%
Therapy line 0.053
 Breast-Ca Neoadjuvant 70 15.6% 58 82.9% 12 17.1%  
Adjuvant 89 19.9% 64 71.9% 25 28.1%  
Metastasis 1st -line 78 17.4% 45 57.7% 33 42.3%  
Metastasis 2nd -line 50 11.2% 37 74.0% 13 26.0%  
Metastasis 3rd -line 20 4.5% 17 85.0% 3 15.0%  
Metastasis ≥4th -line 53 11.8% 42 79.2% 11 20.8%  
Recurrence 1st -line 8 1.8% 6 75.0% 2 25.0%  
Recurrence ≥ 2nd -line 5 1.1% 3 60.0% 2 40.0%  
 Ovarian-Ca Neoadjuvant 1 0.2% 1 100.0% 0 0.0%  
Adjuvant 37 8.3% 29 78.4% 8 21.6%  
Recurrent 37 8.3% 30 81.1% 7 18.9%  
Therapy
 Immune modulation   2 0.4% 2 100.0% 0 0.0% 0.402
 Chemotherapy   278 62.1% 220 79.1% 58 20.9% 0.002
 Antibodies   196 43.8% 143 73.0% 53 27.0% 0.625
 Endocrine   150 33.5% 100 66.7% 50 33.3% 0.011
 Bisphosphonates   129 28.8% 87 67.4% 42 32.6% 0.041
  1. 1p values are not adjusted for multiplicity and have to be interpreted to be exploratory